Anti-TNFRSF12A/TWEAKR/CD266 Antibody (Enavatuzumab)
Catalog No.
F1057
Anti-TNFRSF12A/TWEAKR/CD266 Antibody (Enavatuzumab)
Featured Products
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody that targets the TNF-like weak inducer of apoptosis receptor (TWEAK). TWEAK (Fn14; TNFRSF12A) is the natural ligand of the TWEAK receptor (TweakR) and stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody-dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruit and activate myeloid effector cells to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo.
Quality Control & DataSheet
- View current batch:
-
Purity > 95% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
150 kDa
Dry ice
1062149-33-0
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
PDL-192, Enavatuzumab
100 mM Pro 20 mM Arg pH 5.0. No preservative!
Q9NP84
Human
Unconjugated
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
Human TNFRSF12A / TWEAKR / CD266 HEK293 Cell Line were stained with Anti-TNFRSF12A/TWEAKR/CD266 Antibody (Enavatuzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, The EC50 is 0.04694 ug/mL.
TNFRSF12A / TWEAKR / CD266
Please avoid freeze-thaw cycles.